Targeting Stem Cells in Multiple Myeloma for Improved Outcomes

CureTalks

December 18, 2017

UPCOMING/Recent Talks

Targeting Stem Cells in Multiple Myeloma for Improved Outcomes

with Dr. William Matsui

December 20th, 2017. 5PM EST

Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of a drug-resistant disease that carries a dismal prognosis. Relapse is dependent on stem cell functions. We are talking to Dr. William Matsui of Johns Hopkins University School of Medicine to get a better understanding of the drivers of these functions and how they may lead to novel therapies for relapsed disease.

Panelists

Dr. William Matsui

Gary Petersen

Jack Aiello

Cynthia Chmielewski

Yelak Biru

Understanding the Medical and Legal Aspects of Surrogacy - An Option in Infertility with Dr. Aimee Evyazzadeh & Greggory M Field, Esq

December 14th, 2017. 6PM EST

LISTEN

Surrogacy is a method of assisted reproduction for people who are unable to conceive due to medical complications or any other reason. It is an agreement where a woman agrees to carry a pregnancy for a couple or a person, who will become the baby's parent after birth. Surrogacy has been a controversial issue around the world and involves a lot of complicated contracts that intended parents as well as surrogates need to abide by. We discussed the medical and legal aspects of surrogacy with reproductive endocrinologist Dr. Aimee D. Eyvazzadeh, reproductive/fertility lawyer Greggory M Field, and Emily M Field who became a mother through surrogacy.

Panelists

Dr. Aimee Eyvazzadeh

Greggory M Field, Esq

Emily Dubin Field

Shweta Mishra

Dr. Carl June's CAR-T Cell Journey and the Cancer Treatment Revolution with Dr. Carl June

November 15th, 2017. 1PM EST

LISTEN

FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. It reprograms the body's own immune system to recognise and kill cancer cells. The therapy initially called CAR-T cell immunotherapy and now named Kymriah by Novartis, is approved to treat children and young adults with a recurrent form of blood cancer called acute lymphoblastic leukemia (ALL). Dr. Carl June of University of Pennsylvania is one of the pioneers of CAR-T cell research and leads the team responsible for the historic FDA approval. We discussed Dr. June's CAR-T cell journey to understand the nuances of this therapy. The discussion also brought to focus the opportunity that these engineered immune cells present to cancer treatment, and their possible use in treatment of other cancers.

Panelists